Podcasts about Driver

TOPIC: Dimmable Glass PANEL: Craig Piersma, Gentex; Gary Witzenburg; Gary Vasilash, shinymetalboxes.net; John McElroy, Autoline.tv

For many of us, we would have said at 15 that our greatest fear lied between a Honda Civic and a Lexus, and didn't mind the gap. Parallel parking was the grim reaper of our day and to our new knowledge, he's hung up the sickle in trade for an e-bike. Our second teen has finally crossed over to the Driver's side and we aren't totally sure how we feel about it. On today's show we asked for your teen driving experiences and much more. Enjoy the show!Join us at the Dustin Nickerson Comedy Fans Facebook Group: : http://www.facebook.com/groups/dustinnickersoncomedyWatch the show every week over at Nateland Entertainment:: https://www.youtube.com/channel/UCzAzMoLwjQTuyqu2QFFzvQQDon't Make Me Come Back There Podcast is hosted by Dustin and Melissa Nickerson |Watch Now: https://youtube.com/playlist?list=PL4aMLhoDw6JasL8tgtrlkABlGU8tsiwnH&si=51tUApjDrmh4nz93Podcast produced and edited by Andy Lara at Sun Face Mediahttps://www.dustinnickerson.comhttps://www.andylikeswords.comEmail - dontmakemecomebackthere@gmail.com------------------------------------------------------------------------------------------Come see Dustin LIVE on tour: https://www.dustinnickerson.com/tourFollow and Listen to  Don't Make Me Come Back There: https://apple.co/3A1fbnPSpotify:https://open.spotify.com/show/0qdEVMAx9LqmnqIHmkjOGg?si=341fc47a1a3145e1Watch the new comedy special, Runs in the Family from Dustin Nickerson | (Full Comedy Special) #newcomedy #standupcomedy : https://youtu.be/0Dybn3Atj9kOrder Dustin's book: How to Be Married (To Melissa) today!” https://www.thomasnelson.com/p/how-to-be-married-to-melissa/Give a little more and get a little more from the pod on Patreon!Head to https://www.patreon.com/DustinNickerson for the Patreon Pre Show with behind the scenes podcast rants, exclusive bonus content, and to help support the show.Visit the MERCH shop: https://www.dustinnickerson.com/shopGet social with DustinFacebook: http://www.facebook.com/groups/dustinnickersoncomedyX: https://www.X.com/dustinnickersonInstagram: https://www.instagram.com/dustinnickerson/Tiktok: https://www.tiktok.com/@dustinnickerson#DontMakemeComeBackTherePodcast #dustinnickerson  #Netflix #Comedy #Podcast #primevideo

Darlings, a devastating loss and two dramas still unfolding. James Van Der Beek has died at just 48 after a private battle with colorectal cancer — and friends say he met his final days with remarkable grace and strength. Meanwhile, Jill Zarin is sounding off after being dropped from E!’s upcoming “The Golden Life” over her fiery rant about Bad Bunny’s Super Bowl halftime show. “They didn’t even give me a chance,” she insists, admitting she quickly deleted the video. “People make mistakes. I’m human.” And in the Nancy Guthrie investigation, the briefly detained DoorDash driver has been released — leaving authorities back at square one as the search continues. Rob’s latest exclusives and insider reporting can be found at robshuter.substack.com His forthcoming novel, It Started With A Whisper, is now available for pre-order See omnystudio.com/listener for privacy information.

In this episode: Florida Gov. Ron DeSantis is about to get cut off from an emergency-response fund he raided to rush construction of an immigrant detention facility in the Everglades. There's a showdown brewing between Republican leaders in the state House and Senate over whether he should get to keep it. Plus: The DeSantis administration admits spending opioid settlement money on anti-marijuana TV ads; car dealers are once again using the Legislature to keep themselves between consumers and new cars; and Uber and Lyft want to spend less money insuring their drivers. An update from Day 30 of Florida's 2026 legislative session.Show notesThe bills discussed in today's show: Senate Bill 7040 — Emergency Preparedness and Response Fund/Executive Office of the GovernorPassed the Florida Senate by a 29-10 vote (vote sheet)Senate Bill 7040 amendmentFailed in the Florida Senate by a 12-27 vote (vote sheet)Senate Bill 1562 — Motor Vehicle Manufacturers, Importers, and Distributors and Franchised Motor Vehicle DealersPassed the Senate Transportation Committee by a 7-0 vote (vote sheet)Passed the Senate Commerce and Tourism Committee by a 9-1 vote (vote sheet)House Bill 989 — Motor Vehicle Manufacturers, Importers, and Distributors and Franchised Motor Vehicle DealersPassed the House Industries & Professional Activities Subcommittee by a 16-1 vote (vote sheet)Senate Bill 632 — Transportation Network Company, Driver, and Vehicle Owner InsurancePassed the Senate Banking and Insurance Committee by a 6-3 vote (vote sheet)Senate Bill 1296 — Public Employees Relations CommissionPassed the Senate Governmental and Oversight Accountability Committee by a 6-3 vote (vote sheet)House Bill 1119 — Materials Harmful to MinorsPassed the Florida House of Representatives by an 84-28 vote (vote sheet)The stories discussed in today's show: Florida emergency agency ran up $405 million immigration tab in six monthsAn immigrant detention camp in the Everglades, financed with hurricane-response fundsFlorida state official acknowledges opioid money funded anti-weed campaignFlorida's top cop uses his power to prop up car dealersThe billionaires financing union-busting in FloridaQuestions or comments? Send ‘em to Garcia.JasonR@gmail.comListen to the show: Apple | SpotifyWatch the show: YouTube Get full access to Seeking Rents at jasongarcia.substack.com/subscribe

In this episode of Run the Numbers, CJ Gustafson talks with Rivian CFO Claire McDonough about financing one of the most capital-intensive businesses in the world. They cover long-term investment decisions, capacity planning, cash management as production scales, lessons from Rivian's nearly $14B IPO, the risks of over- and under-building, and why federal EV tax credits matter more than most people think.—SPONSORS:Tabs is an AI-native revenue platform that unifies billing, collections, and revenue recognition for companies running usage-based or complex contracts. By bringing together ERP, CRM, and real product usage data into a single system of record, Tabs eliminates manual reconciliations and speeds up close and cash collection. Companies like Cortex, Statsig, and Cursor trust Tabs to scale revenue efficiently. Learn more at https://www.tabs.com/runAbacum is a modern FP&A platform built by former CFOs to replace slow, consultant-heavy planning tools. With self-service integrations and AI-powered workflows for forecasting, variance analysis, and scenario modeling, Abacum helps finance teams scale without becoming software admins. Trusted by teams at Strava, Replit, and JG Wentworth—learn more at https://www.abacum.aiBrex is an intelligent finance platform that combines corporate cards, built-in expense management, and AI agents to eliminate manual finance work. By automating expense reviews and reconciliations, Brex gives CFOs more time for the high-impact work that drives growth. Join 35,000+ companies like Anthropic, Coinbase, and DoorDash at https://www.brex.com/metricsMetronome is real-time billing built for modern software companies. Metronome turns raw usage events into accurate invoices, gives customers bills they actually understand, and keeps finance, product, and engineering perfectly in sync. That's why category-defining companies like OpenAI and Anthropic trust Metronome to power usage-based pricing and enterprise contracts at scale. Focus on your product — not your billing. Learn more and get started at https://www.metronome.comRightRev is an automated revenue recognition platform built for modern pricing models like usage-based pricing, bundles, and mid-cycle upgrades. RightRev lets companies scale monetization without slowing down close or compliance. For RevRec that keeps growth moving, visit https://www.rightrev.comRillet is an AI-native ERP built for modern finance teams that want to close faster without fighting legacy systems. Designed to support complex revenue recognition, multi-entity operations, and real-time reporting, Rillet helps teams achieve a true zero-day close—with some customers closing in hours, not days. If you're scaling on an ERP that wasn't built in the 90s, book a demo at https://www.rillet.com/cj—LINKS: Claire on LinkedIn: https://www.linkedin.com/in/claire-rauh-mcdonough-5291b946/Rivian: https://rivian.com/CJ on LinkedIn: https://www.linkedin.com/in/cj-gustafson-13140948/Mostly metrics: https://www.mostlymetrics.com—RELATED EPISODES:Why Revenue Recognition Is the Next AI Battleground | Dan Miller of RightRevhttps://youtu.be/TxhTtwmOass—TIMESTAMPS:00:00:00 Craziest Expense Story at Rivian00:01:22 Intro to Claire McDonough00:03:09 Capital Intensity and Vertical Integration at Rivian00:06:44 Raising $14B: How Rivian Planned Its IPO Capital00:10:22 Capacity Planning and Scaling R2 Production00:12:13 Sponsors — Tabs, Abacum, Brex00:15:34 Sweating Existing Capacity vs Overbuilding00:18:22 Winning EV Adoption from ICE Buyers00:22:27 How Federal EV Tax Credits Shape EV Pricing00:26:03 Sponsors — Metronome, RightRev, Rillet00:29:27 R2 as a Driver of Long-Term Profitability00:33:14 Supply Chain as the Critical Path to Launch00:36:53 Product Roadmap as the Anchor for Capital and Headcount00:39:40 Peloton and Flipkart Lessons from Banking00:43:42 Biggest Career Mistake00:44:50 Advice to Younger Self00:47:19 Rivian's Finance Software Stack

The Mark Moses Show is joined by Driver Todd Gilliland of Front Row Motorsports to preview the Daytona 500. Mark broadcasts from The Law Offices of Anidjar & Levine Studios. #daytona #NASCAR Daytona International Speedway

The Mark Moses Show is joined by Driver Zane Smith to preview the Daytona 500 and the new nascar season.  Mark broadcasts from The Law Offices of Anidjar & Levine Studios. #NASCAR #daytona Front Row Motorsports

This week on the Oakley Podcast, host Jeremy Kellett talks with Kirk Waidelich, Chief Commercial Officer at Road Ranger, about how the growing travel stop chain is evolving to better serve truck drivers and auto customers. Drawing on Kirk's 40-year retail background, they discuss Road Ranger's expansion, particularly in Texas, and the changes driven by driver feedback, including competitive fuel pricing, cleaner showers, better food, reserved parking, and stronger loyalty perks, along with the company's commitment to community through St. Jude partnerships. Don't miss this great conversation! Key topics in today's conversation include:Welcome to Today's Episode and Safety Permit Reminder (0:58)  Kirk Joins the Show and Is Introduced (3:23)Kirk's 40-Year Retail Background and Career Path (6:22)Road Ranger History and Ownership Changes (8:01)Texas Growth Strategy and Key Corridors (10:04)What Drivers Want: Fuel Price, Safety, Cleanliness (11:32)Showers, Hotel-Like Upgrades, and Food Value (14:25)Auto vs. Truck Customers and Loyalty Benefits (18:35)Auto/Truck Mix and Spend Differences (21:47)New Store Buildout and Land in Texas (22:59)Testing Grab-and-Go Deli to Reduce Friction (25:30)Reserved Parking, Paid Spots, and Using Points (27:35)St. Jude Partnership and Giving Back (30:21)Kirk's Message to Drivers and Call to Use the App (32:23)Oakley Trucking is a family-owned and operated trucking company headquartered in North Little Rock, Arkansas. For more information, check out our show website: podcast.bruceoakley.com. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Teamsters union has filed a lawsuit to block a new driver choice program at UPS, calling the voluntary buyouts an illegal move to eliminate jobs. Union leaders argue the plan violates their contract, while the company maintains the program is voluntary and necessary to cut costs. A trucking company has agreed to a settlement regarding a deaf driver who was refused employment despite being qualified. Wilson Logistics will pay $50,000 and must implement new training and hiring procedures to comply with the ADA. CSX is making a major investment in its fleet by signing a $670 million deal to acquire and modernize locomotives. The railroad expects the high-tech engines to improve fuel efficiency and reliability starting later this year. Follow the FreightWaves NOW Podcast Other FreightWaves Shows Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of WHAT THE TRUCK?!?, host Malcolm Harris dives into the latest headlines and industry shifts defining the logistics landscape in early 2026. The episode features two deep-dive conversations with experts representing different facets of the supply chain—from the driver's seat to the executive suite. Frontline Perspectives with Avante Jackson: Known as CDL Shorty, Jackson shares his journey as a heart transplant recipient turned instructor. He discusses the critical need for driver mentorship, the realities of the current pay and respect gap, and his advocacy for improved safety standards like underride guards. Strategic Insights with Nathan Adams: The VP of Transportation and Procurement at Uber Freight breaks down how recent winter storms (Fern and Gianna) have disrupted freight flows. Adams provides data-driven insights into tender rejection rates, the tightening of the 2026 market, and how smart shippers are preparing for the upcoming spring surge. ⁠Watch on YouTube⁠ ⁠Subscribe to the WTT newsletter⁠ ⁠Apple Podcasts⁠ ⁠Spotify⁠ ⁠More FreightWaves Podcasts⁠ #WHATTHETRUCK #FreightNews #supplychain Learn more about your ad choices. Visit megaphone.fm/adchoices

Three disabled men are dead, after their driver abandoned the trio in a running van, while he took a 3-hour lunch break. As Carbon Monoxide filled the vehicle the vulnerable men - who couldn't move or shout - choked to death. A fire captain has been caged on almost a dozen counts of child sex abuse; it was his 2nd arrest in 48hrs. Plus, a tram tour at a theme park turns TRAMatic! Jennifer Gould reports. See omnystudio.com/listener for privacy information.

Driver accused of intentionally hitting group outside a California Safeway including Little Leaguers selling beef jerky , Olympic athlete wins bronze medal and then publicly shames himself for cheating on his girlfriend, Drug dealer who was inspired by 'Home Alone' rigged his house with booby traps

In this episode of WHAT THE TRUCK?!?, host Malcolm Harris dives into the latest headlines and industry shifts defining the logistics landscape in early 2026. The episode features two deep-dive conversations with experts representing different facets of the supply chain—from the driver's seat to the executive suite. Frontline Perspectives with Avante Jackson: Known as CDL Shorty, Jackson shares his journey as a heart transplant recipient turned instructor. He discusses the critical need for driver mentorship, the realities of the current pay and respect gap, and his advocacy for improved safety standards like underride guards. Strategic Insights with Nathan Adams: The VP of Transportation and Procurement at Uber Freight breaks down how recent winter storms (Fern and Gianna) have disrupted freight flows. Adams provides data-driven insights into tender rejection rates, the tightening of the 2026 market, and how smart shippers are preparing for the upcoming spring surge. Watch on YouTube Subscribe to the WTT newsletter Apple Podcasts Spotify More FreightWaves Podcasts #WHATTHETRUCK #FreightNews #supplychain Learn more about your ad choices. Visit megaphone.fm/adchoices

REVIEW FOR LATER TODAY Guest: Elizabeth Peek. Peek identifies the housing shortage in America as a primary driver of inflation, creating the widespread perception of a punishing high cost of living.1936 BANK RUN EAST SIDE NYC

Twenty Twenty-Six has only been with us for a month but it has already worn out it's welcome! Military in our streets, internment camps in our cities, an environment that is clearly reaching a tipping point, and a corrupt government run by pedophiles and their protectors. As we watch as our freedoms and rights disappear, take comfort in the fact that the Grinders are still here to spread cheer. It isn't much but we are all in this together. We all have to oppose fascism in our own ways, and deal with our own personal stresses.  A gaming podcast may not be much, but we can help spread the truth and distract the mind from the horrors of reality. Even as our country is fighting for it's life the gaming industry is still thriving. When the weather starts to improve (hopefully) we will see the protests grow to sizes that force change! Strikes, boycotts, and whatever it takes to bring Freedom for All to every person living in this country. A long list of news stories as the number of 2026 releases grows. For the Spring, look forward to the releases of Utawarerumono: Past & Present Rediscovered and Dosa Divas. The Summertime also has a couple of new releases, in Another Eden Begins and Kyoto Xanadue.  With everything going on in America, the Stinkos are growing at an alarming rate. Soon they will need their own show. We are surrounded by so many horrors that it has become impossible for anyone to keep up. America has a corrupt government that is directly responsible for the deaths of millions. A wannabe dictator is changing the rules while no one seems willing to challenge him. The Epstein files continue to be blocked from proper release; the FBI even attempted to hurt the victims. On top of all that, the Grinders say goodbye to an icon. RIP Catherine O'Hare.  After a January that temporarily derailed the show, the Driver's Seat is back to start us off right. Eric want's to know, what are some bad habits you see from gamers you wish they'd get over? The Grinders give you ours. Send us feedback and let us know yours! A special shout out to everyone brave enough to fight fascism and doubly for those fighting it in the bitter cold weather! Jack Frost, puppy killers, and White Supremacists won't stop the spirit of the American people! We sure as hell won't submit to people who abuse children! Join us next week as we dream about Spring and a world without oppression. We love living in a country with such a large diversity of people. We can't let them take away what makes us great, each other.                (Sorry, if this seems disjointed but I didn't want to do my usual spin. The shit that is happening in America is far too important for my silliness.) I feel like I should still say something smartass... You know who isn't in the Epstein files? US!      

Become a supporter of this podcast: https://www.spreaker.com/podcast/the-opperman-report--1198501/support.

Welcome to episode 230 of Sports Management Podcast. Today's guest has lived football from every angle - player, coach, owner, executive, and advisor. Matt Driver is the founder of Soccer Universities and Football Club Advisory Group, and he's worked across Europe and the U.S. helping clubs move from survival mode to scalable success. In this episode, we talk about: Why most soccer clubs struggle financially What American sports get right that football often ignores How fan engagement, data, and commercial thinking will define the future of the game And much more! This is a masterclass in the business of football. SPONSOR: Listeners of the Sports Management Podcast get an exclusive 20% off on SportsPro+ with the code SMPOD20. All you need to do is head to sportspro.com/membership and start exploring today. Time stamps: 00:00 Intro 01:38 Why College Soccer Doesn't Create Pros 03:18 The Wake-Up Call Playing La Liga Clubs 05:30 Creating Real Player Pathways 08:10 Why Most Clubs Are Structurally Broken 11:13 A Bulgarian Club Case Study 15:09 Why Vertical Silos Kill Clubs 16:41 What American Sports Get Right 18:30 Why Fans Jump Between Sports 20:08 Why "We've Always Done It This Way" Fails 26:21 Turning Fan Phones Into Revenue 30:23 Monetizing Club Assets 35:47 Why Fans Must Be Entertained 55:26 Career Advice for Sports Professionals 01:05:54 Why the USL Could Explode Next 01:10:00 Outro Follow Sports Management Podcast on social media Instagram Twitter LinkedIn YouTube www.sportsmanagementpodcast.com

Porque é que o título do filme Táxi Driver, que é "Motorista de Táxi" no Brasil, não teve direito a tradução em Portugal? Porque é que não ficou "O Taxista"? Não faz sentido. Alguém sabe?

今年（ことし）の1月（いちがつ）に運転免許（うんてんめんきょ）を取（と）ったばかりのとらくんですが、今回（こんかい）は、日本（にほん）で運転免許（うんてんめんきょ）を取（と）るには、どんなことをしないといけないのかについて話（はな）しました。海外（かいがい）では、自分（じぶん）で練習（れんしゅう）して運転試験（うんてんしけん）を受（う）けることが多（おお）いと思（おも）いますが、日本（にほん）では、自動車学校（じどうしゃがっこう）という特別（とくべつ）な学校（がっこう）に行（い）って、運転（うんてん）のスキルと、運転（うんてん）についてのルールを習（なら）うのが普通（ふつう）です。そこで、どんなことを習（なら）うのか、どんな勉強（べんきょう）をして、どんな試験（しけん）を受（う）けるのかについて説明（せつめい）しています。ですが、専門用語（せんもんようご）が多（おお）くて、私（わたし）でも、ほとんど何（なに）を言（い）っているのか理解（りかい）できませんでした。なので、今回（こんかい）は聞（き）き取（と）れなくても大丈夫（だいじょうぶ）です。難（むずか）しすぎるので、分（わ）からない部分（ぶぶん）は聞（き）き流（なが）してください。笑Tora has just gotten his driver's license this January, and in this episode, we talked about what you need to do to get a driver's license in Japan.In many countries, people usually practice driving on their own and then take a driving test. However, in Japan, it is common to go to a special school called a driving school, where people learn driving skills as well as the rules of the road.We explain what kind of things you learn there, what kind of studying you have to do, and what kinds of tests you need to take.However, there are so many technical terms that even I couldn't really understand what he was talking about most of the time.So it's totally okay if you can't catch everything this time. It's quite difficult, so please just listen casually and don't worry about the parts you don't understand.

Become a supporter of this podcast: https://www.spreaker.com/podcast/the-opperman-report--1198501/support.

Bradley's Camino de Santiago book, ⁠⁠⁠⁠The Only Way Is West⁠⁠⁠⁠, is a three time international bestseller in Humorous Essays, Action and Adventure Biographies and Travel Writing in the UK, Canada and Australia. To get your eyes on an ebook, your hands on a paperback, or, your ears around the audiobook version, ⁠⁠⁠click here: ⁠mybook.to/amazonbestseller⁠You can also buy Brad a coffee at the link below - he LOVES coffee! :) ⁠⁠⁠⁠https://www.buymeacoffee.com/pilgrimspodcast⁠⁠

Lazlo's youngest is figuring out what to do post ASL surgery, and his oldest doesn't have a curfew. Driver licenses are so confusing, and Lazlo believes in global warming. Lazlo finalizes his Superbowl bet. In Headlines, SlimFast and Lazlo discuss Nancy Guthrie' kidnappers demanding bitcoin, Georgia parents getting investigated for letting their 6 year old scooter to a park, Trump's controversial meme from last night, and much much more! Stream The Church of Lazlo podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!

This episode I am joined by Shawn (Colorado Rideshare Guy), and we cover: Uber in REAL deep trouble legally illegal Doordash Spark accounts WORSE in 2026 vs. 2025 Doordash delivery driver gets 'nasty' while delivering Rideshare Rodeo Brand & Podcast: https://linktr.ee/RideshareRodeo

A Los Angeles grocery store becomes the scene of a deadly car crash. AP correspondent Donna Warder reports.

On this episode of The South Florida Roundup, we went back to the future to discuss Florida's new English-only drivers license test, which in Miami is a historically sore subject — and the subject of a new play that just opened here [1:09]. We also examined what's feeling like a trend: cities in Broward County opting out of law enforcement contracts with the Broward Sheriff's Office [19:22]. And we looked at what's next after a federal judge blocked cancellation of Haitian TPS — and where TPS stands after 35 years [33:12].

Kim Kardashian is generating major buzz as her rumored romance with Formula 1 champion Lewis Hamilton grows more visible, supported by multiple sightings in Paris and the UK, where the two were seen arriving together and spending private time at luxury locations. See omnystudio.com/listener for privacy information.

The Rickey Smiley Morning Show Podcast dives into today’s most urgent and eye‑opening celebrity and news stories. Nicki Minaj continues to spark controversy by doubling down on her support for Donald Trump’s immigration policies, equating border enforcement to protecting a private home—comments that have intensified public debate following her recent appearances with Trump and the revelation that she received a “gold card” giving her a pathway to citizenship. Meanwhile, Kim Kardashian is generating major buzz as her rumored romance with Formula 1 champion Lewis Hamilton grows more visible, supported by multiple sightings in Paris and the UK, where the two were seen arriving together and spending private time at luxury locations. Adding to the week’s explosive topics, GloRilla faces public scrutiny after her sister accused her of failing to support their mother—who allegedly still works at FedEx—despite the rapper’s rising success and multimillion‑dollar net worth, sparking heated debate online about celebrity responsibility to family. The podcast also highlights deeply troubling updates in the disappearance of Savannah Guthrie’s mother, Nancy, after investigators confirmed a ransom note containing specific details about her home and appearance on the night she vanished, though authorities have not validated its authenticity; with concerns heightened due to Nancy’s fragile health and evidence suggesting she was abducted from her home. Website: https://www.urban1podcasts.com/rickey-smiley-morning-show See omnystudio.com/listener for privacy information.

A late-night ride near home. A driver fleeing police. A life cut short. We sit down with Haley Kilman to trace the night her partner, competitive cyclist Blaise Schaeffer, was killed in a hit-and-run—and the relentless search for driver Allen Samir Bautista Milla, who ran on foot and hasn't been seen since. Haley walks us through the frantic morning calls from another state, the agonizing wait for a warrant and a usable photo, and the grind of canvassing Nashville with updated flyers and a $5,000 reward for a lead that results in arrest.We dig into what's known: the attempted traffic stop for erratic driving, the crash damage that disabled the car, the companion who helped identify the suspect, and the jurisdictional complexity at the county line. Beyond the case details, we confront a hard truth about public reaction: how quickly outrage fades and how easily blame shifts to cyclists. The evidence at the scene tells a different story—one about speed, disregard, and a danger zone that would have endangered anyone on that stretch of road. This isn't a bike debate; it's a call for accountability and safety on streets we all share.We also honor Blaise beyond the headlines. He hit a 12,000-mile goal the night before he died. He was top of his class, on homecoming court, a college soccer player, and the kind of person who made rooms feel welcoming. His family is setting up a scholarship at Luther College to keep his legacy alive. Haley's focus is both love and public service: get a face and a name in front of the right eyes, move the investigation forward, and keep another family from living this story. Listen, share the BOLO image, and spread the tip line. If you know anything, call Crime Stoppers at 615-742-7463. Subscribe, share, and leave a review to help this reach the people who can make a difference.BOLO: https://drive.google.com/file/d/1zEBQRobCPy0hFnfkEnp2wrNLh2KfbK5D/view?usp=drive_link______________________________________________________________________________________________SPONSORS: The Try That in a Small Town Podcast is powered by e|spaces!Redefining Coworking - Exceptional Office Space for Every BusinessBook a tour today at espaces.comFrom the Patriot Mobile studios:Don't get fooled by other cellular providers pretending to share your values or have the same coverage. They don't and they can't!Go to PATRIOTMOBILE.COM/SMALLTOWN or call 972-PATRIOTRight now, get a FREE MONTH when you use the offer code SMALLTOWN.Original Brands - Our original sponsor since the beginning!!Original brands is starting a new era and American domestic premium beer, American made, American owned, Original glory.Join the movement at www.drinkoriginalbrands.comPeacemaker Coffee CompanyFounded by retired police officer/chief Chris Morris, Peacemaker delivers clean, low-acidity coffee while supporting police, firefighters, EMS, military, veterans, teachers, dispatchers, and medical personnel through donations and programs. https://www.peacemakercoffeecompany.com/________________________________________________________________________________________________ Follow/Rate/Share at www.trythatinasmalltown.com -For advertising inquiries, email info@trythatinasmalltown.comProduced by Jim McCarthy and www.ItsYourShow.co

Honolulu's Department of Customer Services is ramping up efforts to renew expiring licenses for more than 110,000 motorists; Retired cartographer Tom Patterson discusses the artistry that goes into map-making

Are you ready to accelerate your understanding of retina care?Join Dr. Nemo Patel as he speaks with Dr. Patrick Staropoli, a fellow retina specialist and professional race car driver, in an engaging discussion about Geographic Atrophy (GA) secondary to AMD.In this episode, Dr. Staropoli shares how the principles of racing—split-second decision-making, teamwork, and maintaining focus under pressure—influence his approach to treating GA. Together, they'll explore the evolving GA treatment landscape and emphasize the critical role of early detection and timely referral. Please see full Prescribing Information at http://bit.ly/4jXHTsb. This episode is sponsored by Apellis Pharmaceuticals, which developed its content and compensated the speakers.

Send us a text"Most of us are digging for gold three feet deep... instead of going deep." — David WoodHigh-performance coach David Wood joins RPP to discuss the "Focused CEO" mindset, overcoming trauma, and how to stop being a passenger in your own business.What you'll learn in this episode:How to identify if you are in the driver's seat or the passenger seat of your life.Why high performers often feel scattered and how to fix it in 25-minute increments.David's personal story of Australian upbringing, tragedy, and the path to emotional intelligence.The importance of balancing your worldview with practical systems.Key Episode TakeawaysThe Driver vs. Passenger Mindset: David establishes that most people live as "passengers," reacting to life rather than steering toward a chosen destination.The "Gold Digging" Trap: High achievers often fail by digging a hundred holes three feet deep (shiny object syndrome) instead of focusing on one deep enough to find gold.Childhood Trauma & Hyper-Logic: David recounts the traffic accident that killed his sister when he was seven, explaining how the resulting trauma caused him to shut down his emotions and become hyper-logical for survival.The 25-Year Rebalancing: After achieving "left-brain" success, David spent decades reclaiming "soft skills" like emotional intelligence, vulnerability, and authenticity.The Focus Hierarchy: David introduces his system for radical focus: deciding what your month, week, day, and even your next 25 minutes are about.Accelerating Results: Practical advice on how to reach five-year goals in two years through extreme prioritization and avoiding distractions.Integration for Leadership: Why the "unusual" combination of systems and emotional intelligence is necessary for modern CEOs and entrepreneurs.Comprehensive Video Timestamps00:01:23 – The "Driver vs. Passenger" guarantee: Choosing your destination.00:01:44 – Shiny Object Syndrome and the "Three Feet Deep" trap.00:02:44 – Finding balance: God's guidance and personal control.00:04:12 – David's origins: Growing up in Australia and facing tragedy.00:04:41 – The shutdown: Why trauma creates hyper-logical mindsets.00:05:23 – The search for "Soft Skills": Vulnerability and Authenticity.00:06:45 – Reconnecting with humanity to find true joy.00:07:01 – Goal Acceleration: How to get 5-year results in 2 years.00:07:27 – The "Accidental" Personal Growth program that changed everything.00:08:20 – Cracking the heart open: Transitioning from cynic to seeker.00:15:30 – Defining the Focus Hierarchy for the CEO and Entrepreneur.00:25:45 – The practical 25-minute sprint: How to reclaim your day.00:38:10 – Leadership through authenticity: Connecting with employees and famiSupport the showTHE NOT-SO-FINE-PRINT DISCLAIMER: While we are very thankful for all of our guests, please understand that we do not necessarily share or endorse the same beliefs, worldviews, or positions that they may hold. We respectfully agree to disagree in some areas, and thank God for the blessing and privilege of free will. For more Remarkable Episodes, Inspiration, and Motivation, please visit https://davidpasqualone.com/remarkable-people-podcast/ now!

In a major shift for global trade, shipping giants Maersk and Hapag-Lloyd are returning to the Red Sea route under naval protection. This decision marks a turning point after months of diversions around Africa due to regional instability. Despite a difficult quarter, Heartland Express sees a path to recovery by focusing on improved operating margins. Company executives believe that integrating recent acquisitions and tightening costs will position the fleet for success later this year. Legal developments are also in focus as a long-running lawsuit involving Werner Enterprises nears a final settlement. The deal addresses claims from nearly 100,000 drivers regarding unpaid wages for non-driving time and rest breaks. Follow the FreightWaves NOW Podcast Other FreightWaves Shows Learn more about your ad choices. Visit megaphone.fm/adchoices

What's really happening with freight rates right now—and are you pricing your lanes the right way as capacity tightens? Are new regulations and insurance scrutiny about to reshape carrier operations in 2026?  Today, I break down real-time freight market trends, including stable reefer rates on the Kansas City to Minneapolis lane averaging around $1,285, and why day-of-week pricing strategies are critical for brokers managing customer expectations and protecting margins!  We dig into the rising Minneapolis outbound reefer demand nearing $2,300, the impact of tightening transportation capacity and increased tender rejections in January 2026, plus what Florida's potential $50,000 fines for undocumented drivers and growing compliance enforcement mean for carriers and insurance risk.  Be sure to listen to hear more about the "This Week in Freight" lane analysis segment, delivering actionable DAT-powered pricing insights to help brokers and carriers make smarter decisions, while reinforcing my core philosophy—disciplined pricing, transparency, and long-term relationship building are the keys to surviving competitive pressure and building a sustainable freight business in today's evolving logistics market!   References / Resources https://www.ttnews.com/articles/florida-fines-undocumented-drivers https://www.overdriveonline.com/business/article/15816204/will-insurers-drop-carriers-with-nonenglishspeaking-noncitizen-drivers https://www.freightwaves.com/news/transportation-metrics-show-further-tightening-in-january  

A fog-thick highway. An empty box truck with no traction. One split-second swerve… and you're tumbling off the road into trees, glass, blood, and a headlight that can't cut through the gloom.What happens next isn't a simple winter driving nightmare—it's a survival horror encounter in the woods below the berm, where the fog feels alive, the air reeks of death, and something huge moves on two legs like it owns the night.Trapped in a wreck, hurt badly, and invisible to everyone rushing past overhead, you've got only a few options: climb, hide, or pray the thing outside doesn't find a way in. And if it does… the real terror isn't the crash. It's what came to the crash.If you love creature features, roadside horror, winter driving scares, and tight first-person survival stories with a vicious final sting… buckle up.I Hate Driving a Truck in Winter, but Not Just Because of the Weather by Michael KelsoYou can purchase books from this author here: https://geni.us/michaelkelsoauthorhttps://www.reddit.com/user/Horror_writer_1717/

Route optimization looks perfect on paper, but real drivers live in a very different world.In this episode of Your AI Injection, host Deep Dhillon sits down with Richard Savoie, founder and CEO of Adiona, to unpack the hidden human and economic costs behind fast shipping. Richard shares what he saw firsthand on ride-alongs with drivers, including brutally long days, routes so complex no one else can cover them, and an industry still reliant on tribal knowledge that disappears as experienced workers retire. They explore how traditional route optimization often fails in the real world, producing mathematically “perfect” plans that drivers reject. Richard explains how Adiona's AI blends advanced optimization with real-world experience to create routes drivers actually follow, improving performance while reducing burnout and delivering solutions that work on the ground.Deep and Richard also dive into the counterintuitive economics of sustainability. Most companies don't have spare margin for “green,” so emissions reduction has to pay for itself. They break down how right-sizing fleets and cutting unnecessary miles can slash costs and carbon at the same time, often delivering bigger sustainability gains than buying electric vehicles alone. The conversation also examines why last-mile delivery is so expensive and raises an uncomfortable question about whether more efficient logistics are improving lives and sustainability or quietly accelerating the overconsumption behind modern e-commerce.Learn more about Richard here: https://www.linkedin.com/in/richsavoie/and Adiona here: https://www.adionatech.com/ Check out our related episodes:Is Your Truck Driver Awake? AI-Powered Alerts Are Slashing Fleet Crashes with Gareth Bathers of EXEROS TechnologiesCan AI Help the Energy Industry Plug Costly Methane Leaks? with Ryan Sullivan of Bridger Photonics3 Million Gallons Vanished? The AI Smart City Revolution That's Making Water Waste Visible with Ashwin Chandran of McCord Development

After a tragic hit-and-run accident took the lives of two people, the driver went on trial. Please subscribe to our other podcast, CIVIL, which covers civil cases and trials. Listen to the trailer here - https://podcasts.apple.com/us/podcast/civil/id1634071998 Sponsors in this episode:Boll & Branch - Get 15% off your first order, plus free shipping at Bollandbranch.com/COURT.Ka'Chava -Go to kachava.com and use the code COURT for 15% off.Marley Spoon - Go to MarleySpoon.com/offer/COURT for 45% off your first order and free delivery. Pluto TV - Download the free Pluto TV app for Android, iPhone, Roku, and Fire TV and start streaming now.Post-Production for the show is provided by Jon Keur of Wayfare Recording Co. and this episode was researched and written by Gabrielle Russon.Please support Court Junkie with as little as $3 a month via Patreon.com/CourtJunkie to receive ad-free episodes. Help support Court Junkie with $6 a month and get access to bonus monthly episodes.Follow me on Instagram at CourtJunkieSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Emerson Axsom is officially a full-time World of Outlaws rookie as a stacked field heads to Volusia, while High Limit rolls out notable rule changes for the 2026 season. Plus, a surprising late model team split, ASCS action from DIRTcar Nationals, and more.

In this episode of Your Career GPS, host Brad Minton speaks with career coach Nicolette Hemingway about the importance of building confidence in young professionals. They discuss strategies for understanding personal skills, overcoming perfectionism, and navigating the comparison game. Nicolette emphasizes the significance of networking, mentorship, and maintaining a positive mindset to achieve career growth. The conversation also highlights the value of seeking feedback and the necessity of patience in career development.Guest Info: Nicholette Hemingway is a native of Myrtle Beach, SC and resides in the Metro Area of Warner Robins, GA. She is the Owner and Operator of Nike H Speaks LLC, which provides career coaching services, interview preparation training, résumé writing training, document, and letter writing, along with reviewing and writing résumés. Nicholette has spoken on several in-person and virtual stages, talking about interviewing with Confidence; The ABCs of Interviewing; Celebrate the Small Wins; and Depression and Women of Faith. Nicholette connects with her audiences by being relatable and transparent, because she's been in their places. Nicholette believes that everyone has a story that only they can tell, so that is why it is important to let your voice be heard. Nicholette is an Amazon #1 Best Seller and has self-published 3 books, and they can all be found on Amazon. Nicholette has a passion for putting pen to paper, and God has graced her with the ability to write books that are captivating, inspiring, and informative to readers. She has a Bachelor's Degree in Biology and a Master's Degree in Public Health Administration from the University of South Carolina. Nicholette has 1 beautiful daughter and 1 adorable grandson.Author Page: http://www.amazon.com/author/nhemingway Website: http://www.nikehspeaks.com LinkedIn: https://www.linkedin.com/in/nicholetteh/ 

Dr. Joshua Reuss is back on the podcast to discuss the full update to the living guideline on stage IV NSCLC without driver alterations. He discusses the new evidence and how this impacts the latest recommendations on first-line and subsequent therapeutic options. Dr. Reuss emphasizes the need for shared decision-making between clinicians and patients. He shares ongoing research that the panel will review in the future for further updates to this living guideline, and puts the updated recommendations into context for clinicians treating patients with stage IV NSCLC. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02825    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Joshua Reuss from Georgetown University, co-chair on "Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2026.3.0." It is great to have you back on the show today, Dr. Reuss. Dr. Joshua Reuss: Happy to be here, Brittany. Brittany Harvey: Just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Reuss who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. Dr. Reuss, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer without driver alterations is updated on an ongoing basis. So, what prompted this latest update to the recommendations? Dr. Joshua Reuss: Our committee is tasked with making routine updates to the living guidelines and really keeping them living, right? So, evaluating new data as it is coming in to see, is this practice changing? Is this data that should inform and potentially alter our guideline recommendations so that practitioners and other care providers could really make the best treatment decisions for their patients? So that is something that happens on a more routine basis, but periodically, we are tasked with performing a more comprehensive update of our guideline where we really evaluate every one of our point recommendations, the data associated with these recommendations, to be sure that these are up to date, these are comprehensive, and to see if we need to alter anything in the language of these updates. Brittany Harvey: Excellent. Thank you for providing that background. And yes, this is truly a comprehensive update that goes through all the latest literature. Given that, I would like to review what has changed and what is new in the recommendations. So, what are the updated recommendations on first-line therapy for patients with stage IV non-small cell lung cancer without driver alterations? Dr. Joshua Reuss: So there are two main guidelines that we recommend from this panel. One is a driver mutation-positive guideline and the other is a driver mutation-negative guideline. And I think on first blush, one might look at kind of the recent flurry of approvals and new data and say, well, all the excitement, you know, is in the driver mutation-positive guideline. But I would say that the driver mutation-negative guideline is equally as important and really has several unique challenges associated with it. You know, first and foremost is that there are really a multitude of regimens that can be considered for any one patient. And how to choose between one can be quite difficult and a stressful challenge that clinicians can have, particularly since there are really no randomized studies comparing these regimens in a head-to-head fashion. In addition, you know, these guidelines are really broken down by two key factors. One is disease histology, so namely squamous versus non-squamous histology. And the other is PD-L1 status, broken down into one of three tertiles: PD-L1 high, which is greater than or equal to 50% expression; PD-L1 low, which is 1% to 49% expression; and then PD-L1 negative or unknown. So what you are really looking at, if you do that math, is really six unique patient subpopulations where we need to make a recommendation on one of the multitude of treatment regimens that is approved. And what that means is you are oftentimes really looking at subset and sub-subset level data to help inform clinicians in their treatment decision making, which can be quite challenging because as those small subsets of data is more and more parsed, there are many confounders that can be interjected there. And so I think the committee is tasked with really quite a challenge in terms of how to really communicate and broadcast that data in a way that informs clinicians in making a decision on what is the right treatment for their patient. Brittany Harvey: Absolutely. It can be challenging to interpret that subgroup data across several different studies that are reporting on different regimens and different outcomes. And I appreciate you mentioning the driver mutation-positive guideline as well. Listeners can check out the companion episode with Dr. Puri for more information on what is changed in the driver mutation-positive guideline. Based on that primer, what is new for first-line therapy for patients with stage IV non-small cell lung cancer without driver alterations? Dr. Joshua Reuss: Even though I will say there is not a lot of new trial data that was incorporated into this guideline, there were some updates and just some meaningful long-term data that we incorporated. I think first and foremost, there is a new top-level recommendation in this guideline pertaining to molecular testing, which is absolutely critical in both the driver mutation-positive and driver mutation-negative space. I think we tend to think that, oh, well, molecular testing really only pertains to then finding a driver mutation. But the lack of a mutation is absolutely critical as well, right? Because that is what leads us down the mutation-negative pathway. We also need this molecular testing to assess PD-L1 status. We are seeing emerging data on molecular mutations that might confer resistance to certain immunotherapy-based strategies. So the committee felt strongly that a recommendation on molecular testing is critical to include in both the driver mutation-positive guideline and the driver mutation-negative guideline. I will also say that we are now seeing five and six-year updates from some of the landmark trials of immunotherapy in driver mutation-negative non-small cell lung cancer. It is really incredible to see that in some of these trials, we are seeing very impressive durability of the treatment in the patient subsets that we are commenting on. In others, perhaps that durability is less clear, and I think that leads to challenges in making a recommendation on any one particular regimen. And I think that is nowhere more clear than in the squamous subset. I think that was one perhaps subtle change that is in this guideline where, particularly in the PD-L1 negative squamous population, the committee felt that no one regimen really was worthy of standing above the others. Sometimes I think it is important to really champion one unique regimen if we feel that the data is there to support it. But I think it is equally important to list multiple regimens where the data is less clear. I think another point is that while perhaps there were no new regimens that we have added or that led to other clear changes in the prioritization of one regimen over another, there are other unique data subsets that I think come into play in making a decision and that really are important when looking at the discussion on any one recommendation from this guideline. For example, we know there is emerging data on perhaps the significance of molecular alterations in KEAP1 or STK11 and how that might influence frontline decision-making. You know, there is not a prospective phase III trial in this population, but I think we still need to use that data in certain scenarios to make recommendations for a particular patient. Another example of a trial that, again, did not change our recommendations, but I think one can incorporate in their decision making is the KEYNOTE-598 trial. Now, this is not a new study, but what it studied was pembrolizumab versus pembrolizumab plus ipilimumab in a PD-L1 high subset, and found that the addition of ipilimumab to pembrolizumab in the PD-L1 high population did not significantly improve clinical efficacy. And so while pembrolizumab plus ipilimumab is not an approved regimen, it is hard to extrapolate that to our combination treatments that are approved. I think some clinicians might find that data valuable when making a frontline treatment decision on a patient who has PD-L1 high status. So a bit of a whirlwind tour, but I think there are still multiple factors that went into this guideline that are important to review when making treatment decisions for any one patient. Brittany Harvey: Absolutely. I think what you just mentioned in having that upfront molecular testing is really key for individualized patient care. And the evidence summaries that you provide in addition to the recommendations are really important for clinicians to be able to refer to as they are making decisions in their clinic. So then beyond those changes for first-line therapy, what is updated for second-line and subsequent therapies? Dr. Joshua Reuss: For second-line and subsequent therapies, we did see one new treatment recommendation join these ranks, and that was telisotuzumab vedotin. Telisotuzumab vedotin, quite a mouthful. That is an antibody-drug conjugate. I like to think of that as smart chemotherapy, targeted chemotherapy, where you are trying to utilize some aspect of a marker that is selectively expressed or overexpressed on the cancer surface to then shepherd in the anticancer molecule, a highly potent chemotherapeutic in the case of currently approved antibody-drug conjugates, to exert antitumor killing effect. So in this case, the antibody-drug conjugate telisotuzumab vedotin targets MET overexpression. So telisotuzumab is an antibody targeting MET, and that is conjugated to an MMAE highly potent chemotherapeutic payload called vedotin. So we know MET can be selectively expressed and overexpressed in non-small cell lung cancer in both driver mutation-positive and mutation-negative subsets. The data that led to this approval was from the phase II LUMINOSITY trial which evaluated telisotuzumab vedotin, or Teliso-V, in many subsets. But the subset that really showed promise and was expanded was the EGFR wild-type, non-squamous, non-small cell lung cancer population with MET overexpression. And so in 78 patients with high levels of expression, the response rate here was 34.6%, median progression-free survival of 5.5 months, and a median overall survival of 14.6 months. With an overall acceptable safety profile; grade 3 or higher adverse events, neuropathy was perhaps the most common at 7%, also increased ALT at 3.5%, and pneumonitis at 2.9%. Now this was phase II data that led to an accelerated approval. There is an ongoing phase III study randomizing patients with high expression to Teliso-V versus docetaxel. That is the phase III TeliMET study. But it is nice that we now have another option for patients, perhaps a more biomarker-directed option with, again, this MET overexpression. And again, it further reinforces the importance of molecular testing in patients with traditionally driver mutation-negative non-small cell lung cancer, whether that is upfront or at progression, and in particular utilizing immunohistochemistry to assess MET expression in these patients. And this does join another ADC that we had previously made an update in our recommendation, which is trastuzumab deruxtecan, which is approved for those patients with HER2-overexpressing non-small cell lung cancer. So just again to reiterate the importance of molecular testing in patients both at the outset of their treatment and upon progression on frontline therapy. Brittany Harvey: Definitely. It is great to have this new antibody-drug conjugate join the treatment options, and as you mentioned, very important in this case to have that molecular testing done at the outset and at progression. So then in your view, what should clinicians know as they implement this living guideline, and how do these changes impact patients with non-small cell lung cancer? Dr. Joshua Reuss: Because there are so many different regimens that one can consider for any one patient, I think it is easy to become overwhelmed and stress on, "Am I making the right choice for my patient?" And I think one of the key take home points is that in many cases, there is no one right regimen. And I think one has to weigh several factors. It is the treatment schedule. It is the toxicity profile. It is the molecular profile of the patient. It is the patient preference. You know, there are so many factors here. And I would like to draw the reader and viewer's attention to an important section of these guidelines, particularly the Patient and Clinician Communication section, where we have a box focused on discussion points between patients and clinicians, which I think focuses on several of the high-level points that one can emphasize in making these decisions, ranging on things from: what are the goals of the treatment? What are the risks and benefits to any one approach? What are comorbidities that should be factored in? Common concerns, toxicity management, clinical trial consideration. All of these factors that I think are incredibly important in making that frontline treatment decision and implementing a regimen that both the clinician and, more importantly, the patient feels comfortable with. Brittany Harvey: It is really important that there is shared decision-making in these scenarios. And I think that patient-clinician communication section can tease out some of those preferences from the patient end and talk through the risks and benefits of different regimens as well. As we mentioned at the top of this episode, this guideline is a living guideline and updated on an ongoing basis. So what is the panel examining and keeping an eye on for future updates to this guideline? Dr. Joshua Reuss: So I think there are a lot of exciting new therapies and more up-to-date trials that we are anxiously awaiting the results of on our committee, and I think the oncology community in general is awaiting the results of. When we will have these results, I think, is a bit of an open-ended question, but I can give some insight on several of the trials that our committee is really keeping a close eye on. One that we have mentioned for several guideline iterations is the ECOG-ACRIN INSIGNA trial. This is a phase III clinical trial comparing pembrolizumab versus pembrolizumab plus carboplatin and pemetrexed chemotherapy in PD-L1 positive, non-squamous, non-small cell lung cancer. We talk about there being different regimens that can be considered in PD-L1 positive and PD-L1 high subsets, namely immunotherapy alone or immunotherapy plus chemotherapy, but there is no direct head-to-head comparison here. So this trial hopefully will answer that question. It has now finished accrual. There are other very interesting molecules and trials. I think another interesting compound is ivonescimab. This is a PD-1/VEGF bispecific antibody that is currently approved in China as monotherapy in patients with PD-L1 positive non-small cell lung cancer based off of the HARMONi-2 trial, where the progression-free survival of this bispecific antibody, ivonescimab, appeared superior to pembrolizumab. And we are looking closely at ongoing trials to see if these results will be replicated in an ex-China population. And if so, I think it could have a real impact and change on our guidelines. Still other very interesting things. There are obviously confirmatory studies for antibody-drug conjugates, such as the TeliMET study that I alluded to earlier, and many promising antibody-drug conjugates, both bispecific and trispecific antibody-drug conjugates, that hopefully can inform practice. And then there are several unique subsets of populations that I think we now are utilizing data on to make decisions, but a lot of that is retrospective in small subsets where we do not have that prospective data. And there are several trials ongoing in some of these subsets to try to gain clarity on what regimen may be the best for patients. One example is the phase III TRITON trial, which is looking at comparing CTLA-4 containing regimen, particularly the POSEIDON regimen of durvalumab plus tremelimumab and chemotherapy, versus the KEYNOTE-189 regimen, which is pembrolizumab plus carboplatin and pemetrexed, in patients with non-squamous, non-small cell lung cancer that have alterations in either KRAS, KEAP1, and/or STK11. There is a lot of both preclinical and clinical data to suggest that patients with these alterations in STK11 and KEAP1 may be more resistant to a PD-1 based treatment approach, and perhaps the incorporation of CTLA-4 can lead to a more meaningful response in this unique subset. Obviously, that data, it is retrospective, it is in small subsets. And when you add in a CTLA-4 molecule, you are also introducing greater risk for toxicity. So this trial is going to be very important in elucidating: is there a benefit in that unique subset? Does that data that we see retrospectively in this small subset hold true when evaluated in a prospective fashion? So while our guideline, our most recent comprehensive panel update, may not have had a lot of new data in it that has influenced frontline treatment decision-making, I think the future is bright and there are a lot of novel studies and novel treatments on the horizon that will hopefully improve the outcomes for our patients. Brittany Harvey: Absolutely. We will look forward to the results of those ongoing trials to provide more options and particularly clarity for patients with non-small cell lung cancer and to inform this guideline and its many updates to come. So I want to thank you so much for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Reuss. Dr. Joshua Reuss: Thank you so much. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines App available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Dr. Sonam Puri discusses the full update to the living guideline on stage IV NSCLC with driver alterations. She shares a new overarching recommendation on biomarking testing and explains the new recommendations and the supporting evidence for first-line and subsequent therapies for patients with stage IV NSCLC and driver alterations including EGFR, MET, ROS1, and HER2. Dr. Puri talks about the importance of this guideline and rapidly evolving areas of research that will impact future updates. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02822    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Sonam Puri from Moffitt Cancer Center, co-chair on "Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline, Version 2026.3.0." It's great to have you here today, Dr. Puri. Dr. Sonam Puri: Thanks, Brittany. Brittany Harvey: And then just before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Puri, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to dive into the content that we're here today to talk about, Dr. Puri, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer with driver alterations is updated on an ongoing basis. So, what data prompted this latest update to the recommendations? Dr. Sonam Puri: So Brittany, non-small cell lung cancer is one of the fastest-moving areas in oncology right now, particularly when it comes to targeted therapy for driver alterations. New data are emerging continuously from clinical trials, regulatory approvals, real-world experience, which is exactly why these are living guidelines. The goal is to rapidly integrate important advances as they happen, rather than waiting for years for a traditional update. Since the last full update of the ASCO Stage IV Non-small Cell Lung Cancer Guideline with Driver Alterations published in 2024, there have been seven new regulatory approvals and changes in first-line therapy for some driver alterations. [This version] of the "Stage IV Non-small Cell Lung Cancer Guidelines with Driver Alterations" represents a full update, which means that the panel reviewed and refreshed every applicable section of the guideline to reflect the most current evidence across therapies including sequencing and clinical decision-making. This is to ensure that clinicians have up-to-date practical guidelines that keep pace with how quickly the field is evolving. Brittany Harvey: Absolutely. As you mentioned, this is a very fast-moving space and this full update helps condense all of those versions that the panel reviewed before into one document, along with additional approvals and new trials that you reviewed during this time period. So then, the first aspect of the guideline is there's a new overarching recommendation on biomarker testing. Could you speak a little bit to that updated recommendation? Dr. Sonam Puri: Yeah, definitely. So the panel has discussed and provided recommendations on comprehensive biomarker testing and its importance in all patients diagnosed with non-small cell lung cancer. Ideally, biomarker testing should include a broad-based next-generation sequencing panel, rather than single-gene tests, along with immunohistochemistry for important markers such as PD-L1, HER2, and MET. These results really drive treatment decisions, both in frontline settings for all patients diagnosed with non-small cell lung cancer and in subsequent line settings for patients with non-small cell lung cancer harboring certain targetable alterations. Specifically in the frontline setting, it helps determine whether a patient should receive upfront targeted therapy or immunotherapy-based approach. We now have strong data that shows that complete molecular profiling results before starting first-line therapy is associated with better overall survival and actually more cost-effective care. Using both tissue and blood-based testing can improve likelihood of getting actionable results in a timely way, and we've also provided guidance on platforms that include RNA sequencing, which are specifically helpful for identifying gene fusions that might be otherwise missed with other platforms. On the flip side, outside of a truly resource-limited setting, single-gene PCR testing really should not be routine anymore. This is what the panel recommends. It's less sensitive and inefficient and increases the risk of missing important actionable alterations. Brittany Harvey: Understood. I appreciate you reviewing that recommendation. It really helps identify critical individual factors to match the best treatment option to each individual patient. So then, following that recommendation, what are the updated recommendations on first-line therapy for patients with stage IV non-small cell lung cancer with a driver alteration? Dr. Sonam Puri: Since the last full update in 2024, there have been four additional interim updates which were published across 2024 and 2025. Compared to the last version, there have been several updates which have been included in this full update. One of the most important shifts has been in first-line treatment of patients with non-small cell lung cancer harboring the classical, or what we call as typical, EGFR mutation. The current version of the recommendation is based on the updated survival data from the phase III FLAURA2 and MARIPOSA studies, based on which the panel recommended to offer either osimertinib combined with platinum-pemetrexed chemotherapy or the combination of amivantamab plus lazertinib in the first-line treatment of classical EGFR mutations. And these recommendations, as I mentioned, are grounded in the results of the FLAURA2 and MARIPOSA trials, both of which demonstrated improvement in progression-free survival and overall survival compared to osimertinib alone in patients with common EGFR mutations. That being said, the panel actually spent significant time discussing the toxicities associated with these treatments as well. These combination approaches come with higher toxicity, longer infusion time, increased treatment frequency. So while combination therapy is now recommended as preferred, the panel has recommended that osimertinib monotherapy remains a reasonable option, particularly for patients with poor performance status and for those who are not interested in treatment intensification after knowing the risks and benefits. Brittany Harvey: Absolutely. It's important to consider both those benefits and risks of those adverse events that you mentioned to match appropriately individualized patient care. So then, beyond those recommendations for first-line therapy, what is new for second-line and subsequent therapies? Dr. Sonam Puri: So this is a section that saw several major updates, particularly again in the EGFR space. The first was an update on treatment after progression on osimertinib for patients with classical EGFR mutation. Here the panel recommends the combination of amivantamab plus chemotherapy, and this recommendation was based on the phase III MARIPOSA-2 trial, which compared amivantamab plus chemotherapy with chemotherapy alone with progression-free survival as the primary endpoint. The study met its primary endpoint, showing an improvement in median PFS with the combination of amivantamab plus chemotherapy compared to chemotherapy alone. And as expected, the combination was associated with higher toxicity. So, although the panel recommends this regimen, the panel emphasizes that patients should be counseled on the side effects which may be moderate to severe with the combination therapy approach. In addition, a new recommendation was added for patients who are not candidates for amivantamab plus chemotherapy. In those cases, platinum-based chemotherapy with or without continuation of osimertinib may be offered, and the option of continuing osimertinib with chemotherapy was recommended and supported by data from a recently presented phase III COMPEL study, which randomized 98 patients with EGFR exon 19 deletion or L858R-mutated advanced non-small cell lung cancer who had experienced no CNS progression on first-line osimertinib, and these patients were randomized to receive platinum-pemetrexed chemotherapy with osimertinib or placebo. Although this study was small, it demonstrated a PFS benefit with continuation of osimertinib with chemotherapy, and this approach may be appropriate for patients without CNS progression who prefer or require alternatives to more intensive treatment strategies. Next was an update on options for patients with EGFR-mutated lung cancer after progression on osimertinib and platinum-based chemotherapy. Here the panel recommended that for patients whose disease has progressed after both osimertinib and platinum-based chemotherapy, a new drug known as datopotamab deruxtecan can be offered as a treatment option. And this treatment recommendation was based on evaluation of pooled data from the TROPION-Lung01 and TROPION-Lung05 study, in which in the pooled analysis about 114 patients with EGFR-mutant non-small cell lung cancer were treated with Dato-DXd, 57% of whom had received three or more prior lines of treatment, and what was observed was an overall response rate of 45% with a median duration of response of 6.5 months. So definitely promising results. Next, we focused on updates to subsequent therapy options for patients with another type of EGFR mutation known as EGFR exon 20 insertion mutations. In this section, the panel added sunvozertinib as a subsequent line option after progression on platinum-based chemotherapy with or without amivantamab. Sunvozertinib is an oral, irreversible, and selective EGFR tyrosine kinase inhibitor with efficacy demonstrated in the phase II WU-KONG6 study conducted in Chinese patient population. In this study, amongst 104 patients with platinum-pretreated EGFR exon 20 mutated non-small cell lung cancer, the observed response rate was 61%. Staying in the EGFR space, the panel added a recommendation for patients with acquired MET amplification following progression on EGFR TKI therapy. In these situations, the panel recommended that treatment may be offered with osimertinib in combination with either tepotinib or savolitinib. As our listeners may know, MET amplification occurs in approximately 10% to 15% of patients with EGFR-mutated non-small cell lung cancer when they progress on third-generation EGFR TKIs, and detection of MET amplification is done with various methods, such as tissue-based methods like FISH, NGS, and IHC, as well as ctDNA-based NGS with variable cut-offs. Over the last few years, several studies have informed this recommendation. I'm going to be discussing some of them. In the phase II ORCHARD trial, 32 patients with MET-amplified non-small cell lung cancer after progression on first-line osimertinib were evaluated, where the combination of osimertinib plus savolitinib achieved an overall response rate of 47% with a duration of response of 14.5 months. More recently, the phase II SAVANNAH trial reported outcomes in 80 patients with MET-amplified tumors after progression on osimertinib, and in this patient population, the combination of savolitinib and osimertinib achieved an overall response rate of 56% with a median PFS of 7.4 months. And lastly, the phase II single-arm INSIGHT 2 trial assessed the efficacy of osimertinib plus tepotinib in patients with advanced EGFR-mutant non-small cell lung cancer who had disease progression following first-line osimertinib therapy. And in this study, in a cohort of 98 patients with MET-amplified tumors confirmed by central testing, the overall response rate with the combination was 50% with a duration of response of 8.5 months. So definitely informing this guideline recommendation. Next, we had an update on recommendation in patients with ROS1-rearranged non-small cell lung cancer. For patients with ROS1-rearranged non-small cell lung cancer, the panel recommended specifically for patients who progressed after first-line ROS1 TKIs, the addition of taletrectinib as a new option alongside repotrectinib. And this recommendation was based on analysis of the results of the TRUST-I and TRUST-II studies, which showed that amongst 113 tyrosine kinase inhibitor-pretreated patients, taletrectinib achieved a confirmed overall response rate of 55.8% with a median duration of response of 16.6 months and a median PFS of 9.7 months, a very promising agent. Finally, for patients with HER2 exon 20 mutated non-small cell lung cancer, the panel added two new oral HER2 tyrosine kinase inhibitors, zongertinib and sevabertinib, as options in addition to T-DXd and after exposure to T-DXd. These recommendations are based on early phase data from two trials: the phase I Beamion LUNG-01 study, which evaluated zongertinib, and the phase I/II SOHO-01 study that evaluated sevabertinib. In this study, zongertinib demonstrated an overall response rate of 71% in previously treated patients, with an overall response rate of 48% amongst patients who had received prior HER2-directed ADCs including T-DXd. Sevabertinib in its early phase study showed an overall response rate of 64% in previously treated but HER2 therapy-naive patients, and an overall response rate of 38% in patients previously exposed to HER2-directed therapy. The panel believes that both agents had manageable toxicity profile and represent meaningful new options for this patient population. Brittany Harvey: Certainly, it's an active space of research, and I appreciate you reviewing the evidence underpinning all of these recommendations for our listeners. So, it's great to have these new options for patients in the later-line settings. And given all of these updates in both the first and the later-line settings, what should clinicians know as they implement this latest living guideline update, and how do these changes impact patients with non-small cell lung cancer? Dr. Sonam Puri: Some great questions, Brittany. I think for clinicians when implementing this update, I think about two practical steps. First is reiterating the importance of comprehensive biomarker testing. That is the only way to identify key drivers and resistance mechanisms that we are now targeting. And second, picking a first-line strategy that balances efficacy and toxicity and patient preference for your specific patient. I think informed decision-making, shared decision-making is more important than any time right now. It has always been important, but definitely very important now. For patients, this guideline brings recommendations on more personalized treatment options for both first-line and post-progression settings, which potentially means better outcomes. But it is also very important for our patients to continue to have informed conversations about side effects, time commitment, and what matters most to them with their providers. The panel in this version of the guideline specifically acknowledges the real-world barriers that prevent patients from receiving guideline-concordant therapy, including challenges with access to comprehensive molecular testing and treatment availability, and the panel emphasizes on the importance of shared decision-making, and we provide practical discussion points to help clinicians navigate these conversations with the patient. In addition, the panel has also addressed common real-world clinical complexities, such as treating elderly or frail patients, managing multiple chronic conditions, considerations around pregnancy and fertility, and certain disease scenarios such as oligoprogression or oligometastatic disease. And where available, the guideline summarizes this existing data to support informed individual decision-making in these complex situations. Brittany Harvey: Shared decision-making is really paramount, especially with all of the options and weighing the risks and benefits and considering the individual circumstances of each patient that comes before a clinician. We've talked a lot about all of the new studies that the panel has reviewed, but what other studies or areas of research is the panel examining for future updates to this living guideline as it continues to be updated on an ongoing basis? Dr. Sonam Puri: Yes, definitely, so much to look forward to, right? Looking ahead, the panel is closely monitoring several rapidly evolving areas that are likely to shape future updates of the guideline. This includes emerging data from ongoing later-phase studies, particularly the studies that are evaluating these new targeted agents moving to earlier lines of therapy, alongside studies evaluating additional combination strategies or more refined approaches to treatment sequencing. We're also closely watching advances in biomarker testing, the evolving understanding of resistance mechanisms, development of new targets, and promising therapeutic agents. I think ultimately the living guideline exists to help clinicians and patients navigate this rapidly evolving field, and we would like to ensure that scientific advances are rapidly translated into better, more personalized patient care. Brittany Harvey: Definitely. We'll look forward to those updates from those ongoing trials and future areas of research that you mentioned to provide better options for patients with non-small cell lung cancer and a driver alteration. So I want to thank you so much for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Puri. Dr. Sonam Puri: Thanks so much. Thanks so much for the opportunity. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. There's also a companion episode with Dr. Reuss on the related living guideline on stage IV non-small cell lung cancer without driver alterations that listeners can find in their feeds as well. And if you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

The government has announced the second practical driving test will be gone from January next year. Driving instructor Lynn Holland spoke to Corin Dann.

Join Ivoclar (AND US!) this February at LMT Lab Day in Chicago. Ivoclar will be offering 16 different educational lectures over the three-day event, giving dental professionals plenty of opportunities to learn, connect, and grow. Visit labday.com/Ivoclar to view the full schedule and register, and be sure to stop by and see the Ivoclar team in the Windy City. Walking the Lab Day Chicago floor? Make it worth it. Stop by the FOLLOW-ME! hyperDENT booth (E-27, East Hall) and take part in their Milling Roadmap—a quick, scavenger-hunt-style activity that leads you to key milling partners like Axsys, Imagine, DOF, and Roland. Collect stamps at booths you're likely visiting anyway and get entered to win some great giveaways—including this year's grand prize: a foldable Honda electric scooter. You're already walking the floor. Now it might carry you. Come see and talk to Elvis and Barb at all these amazing shows coming up in 2026* Cal-Lab Association Meeting in Chicago Feb 19-20 https://cal-lab.org/ LMT Lab Day Chicago Feb 19-21 https://lmtmag.com/lmtlabday Dental Lab Association of Texas Meeting in Dallas Apr 9-11 https://members.dlat.org/ exocad Insights in Mallorca, Spain Apr 30 - May 1 https://exocad.com/insights-2026 This week Elvis and Barb sit down with Helen Tanaka — a removable, implant, and digital workflow specialist whose career started in one of the most relatable ways possible: as a dental lab driver. What began as a job delivering cases quickly turned into a full-blown passion once she stepped inside the lab and saw what technicians were creating. From trimming dies and waxing copings to managing labs, supporting implant surgeries, teaching doctors chairside, and leading removable and implant teams, Helen shares a journey built on curiosity, persistence, and a deep drive to understand the why behind everything in dental technology. Helen talks about working her way through crown and bridge fundamentals before discovering her true passion in removables, dentures, implants, and occlusion. After getting real-world lab experience, she attended dental technology school, studied all six specialties, and continued expanding her knowledge through advanced occlusion training and continuing education. She explains why understanding morphology, materials, and occlusal principles is critical — especially today — and why technicians must know more than just the steps of fabrication. For Helen, dentures and implant prosthetics offer the ultimate puzzle, combining anatomy, function, and problem-solving in ways that keep her constantly engaged. The conversation dives deep into digital dentistry, guided surgery, and removable workflows, with Helen sharing her early experiences launching digital denture and sleep appliance programs long before the workflows were polished. She discusses digital record capture, stackable surgical guides, implant planning, photogrammetry, and where digital still needs improvement — especially for removable prosthetics. While she embraces technology, she stresses that software is only as good as the technician behind it, and that skipping fundamentals creates bigger problems later. Digital is powerful, but it doesn't replace understanding. Education is a major theme throughout the episode. Helen regularly teaches doctors and technicians, speaks at courses, supports live implant conversions, and works with dental students. She emphasizes that many clinicians today lack confidence in dentures and removable workflows, often because fundamentals are under-taught, and she sees technicians as essential partners in closing that gap. She and the hosts discuss how removable cases are frequently rushed, underpaid, and misunderstood — even though they replace a critical body function — and why slowing down, capturing correct records, and returning to basics solves many of the “mystery” failures labs see every day. Helen also shares stories from her time with large organizations and clinical teams, including MicroDental, ClearChoice, Arklign, and implant education centers, where she has worked in technical service, management, training, and quality oversight roles. She talks about networking, mentoring, never burning bridges, and investing in people coming up in the industry. Her approach to both dentistry and life centers around curiosity and accountability — always asking why, always backing decisions with data, and always trying to do the right thing even when no one is looking. Throughout the episode, the energy stays fun and honest, with stories about speeding delivery runs, early digital growing pains, chairside save-the-case moments, and the reality of fixing cases that skipped key steps. Helen brings passion, technical depth, and a strong belief that knowledge should be shared, not guarded. It's a conversation about growth, fundamentals, digital evolution, and why great technicians still matter more than ever. If you want to grow your business, you need clear insight into what's happening inside your operation and across your customer journey. That's where Icortica comes in. At Canadian Dental Labs, Icortica has become a cornerstone of how we operate—giving us at-a-glance visibility into performance, helping us focus our efforts, spot opportunities early, and solve problems before they grow. It takes the guesswork out of decision-making and shows us what to do next. Plus, the Icortica team is incredibly responsive and feels like a true partner in our success. If you're serious about growing your business and understanding your customers better, Icortica can get you there. Learn more at icortica.com/voices — Icortica, helping dental labs grow. Join us at exocad Insights 2026, happening April 30–May 1, 2026, on the stunning island of Mallorca, Spain. This two-day event features powerhouse keynotes, hands-on workshops, live software demos, and top-tier industry showcases—all in one unforgettable setting. Barb and Elvis will be on site bringing you exclusive interviews, plus don't miss the FIRST 5k run on the coast! And of course, cap it all off with the legendary exoGlam Night under the stars. Tickets are limited. Visit exocad.com/insights-2026 and use code VFTBPalma15 for 15% off.Special Guest: Helen Tanaka.

Send us a textWe continue with part 2 of the Sovereignty of God. In this episode, we look at what John MacArthur called the most hated doctrine in all of Christianity - The Doctrine of Election. Why is it so hated? Why does it trigger people like nothing else? What does the Bible say about election? Why does it seem like some verses in Scripture imply that salvation is open to everyone? And most importantly, why is understanding the Sovereignty of God as it pertains to our salvation crucial for a rock-solid foundation?Thanks for tuning in! Be sure to check out everything Proverbs 9:10 on our website, www.proverbs910ministries.com! You can also follow us on Facebook, Instagram, Rumble, YouTube, Twitter, Truth Social, and Gettr!

Personal injury and commercial litigation lawyer Tom Paris joins Karen Conti to discuss the difference between liability insurance, collision insurance, and comprehensive coverage. Tom also explains the benefits of an umbrella policy and how underinsured and uninsured motorist coverage works.

After waking up in the wrong state inside a Nissan X-Terra that isn't his, a seasoned anomaly hunter realizes death didn't end his mission—it duplicated it. As the SCP Foundation closes in and reality starts respawning people where they shouldn't exist, survival becomes a high-speed puzzle with no clear rules and no reset button. Listen ad-free + bonus stories with a 7-day FREE trial of ⁠SCP Premium⁠. Cancel anytime. No commitment. This story is derived from ⁠The SCP Foundation Database⁠ and is released under Creative Commons Sharealike 3.0.⁠ ⁠⁠⁠⁠https://creativecommons.org/licenses/by-sa/3.0/⁠⁠⁠ Author: Jake Bible * * * CONTENT DISCLAIMER: This episode contains explicit content not limited to intense themes, strong language, and depictions of violence intended for adults. Parental guidance is strongly advised for children under the age of 18. Listener discretion is advised.  #thescpexperience #scp #scpfoundation #scpencounters #securecontainprotect #scpstories Learn more about your ad choices. Visit megaphone.fm/adchoices

Fatima Bennerson: Fatima continues to get attention by being a huge piece of shit to people trying to do their jobs.SkipTheMan: A jump scare in January as we are introduced to SkipTheMan and his puppetsPalette Cleansers: The Challenger Explosion is a hoax, kid kills dad over Switch and a car crashes into a school. We got it all.THE BEAR!, FUCK YOU, WATCH THIS!, IRON MAIDEN!, HALLOWED BE THY NAME!, JAMIE THOMAS!, WELCOME TO HELL!, GOATED!, DOCTOR!, NA!, 5 YEAR SHOT GLASSES!, EPISODE 400!, ROAD TO 900!, PART TWO CHARACTERS!, SCHIZO MEEMAWS!, FATIMA BENNERSON!, AIRPORT!, WENDY'S!, TALK SHIT!, ATTENTION!, POINT OF VIEW!, START SHIT!, INSUFFERABLE!, GASSED UP!, INTERNET!, WORST PERSON!, STARS HOLLOW!, WARNER BROS!, GILMORE GIRLS!, CUT THE LINE!, VETERAN!, CAN'T STAND!, SKIP THE MAN!, RONALD COATS!, CHEATING HEART!, TIKTOK!, TEXAS CHAINSAW MASSACRE!, SCARY!, SPOOKY!, ROBOCOP!, TOXIC WASTE!, SKIP!, GUY THAT SAYS FOOD WRONG!, MEALS!, INSTAGRAM!, IG!, FIRST AMENDMENT!, COMMIE MIKE!, CHALLENGER EXPLOSION!, HOAX!, ALIVE!, STILL ALIVE!, HIDE IN PLAIN SIGHT!, CITY COUNCIL!, GOVERNMENT BUILDINGS!, ITALIAN MARBLE!, NATION'S CAPITOL!, PALETTE CLEANSER!, KID KILLS DAD OVER SWITCH!, GUN SAFE!, 11 YEARS OLD!, PERFECT AGE!, CRIME!, GRITTY!, DRIVER!, MIDDLE COLLEGE HIGH SCHOOL!, META GLASSES!, CRASH!, You can find the videos from this episode at our Discord RIGHT HERE!

On the four year anniversary of Karen Read's murder of John O'Keefe, we go back and look at how her innocence fraud campaign began without the involvement of Aidan “Turtleboy” Kearney. Why was CourtTV pushing the killer's innocence fraud narrative in September of 2022? Show Sponsor - "Love Isn't Always the Answer" Shelley Levisay - https://a.co/d/bnYcYy9 GetGet access to exclusive content & support the podcast by a Patron today! https://patreon.com/robertaglasstruecrimereportThrow a tip in the tip jar! https://buymeacoffee.com/robertaglassSupport Roberta by sending a donation via Venmo. https://venmo.com/robertaglassBecome a chanel member for custom Emojis, first looks and exclusive streams here: https://youtube.com/@robertaglass/joinShow Notes:Innocence Fraud Watch “QUESTIONS For Chanley Shá Painter & Vinnie Politan & Court TV Re: Statements Made On September 22nd 2022 On Cop Killer Karen Read Case. Incl. Molly Parmer “ - https://x.com/innocencefraudw/status/2016676297020178559?s=46&t=QYSCN5--uh3-3EcMJ5GVBwVoyage ATL - Interview with Molly Parmer - https://www.voyageatl.com/interview/meet-molly-parmer-of-parmer-law/Innocence Fraud Watch “Kate Peter Rants on Spaces on X” - https://rumble.com/v74yzmm-kate-peter-ranting.htmlInnocence Fraud Watch “Lydia Rodarte Quayle is a Liar” - https://rumble.com/v74a5ww-lydia-rodarte-quale-from-the-fourensic-room-is-a-liar.htmlCourtTV “Exclusive Security Video Released in Read Case “ https://youtu.be/Pdq8Kd_hMJo?si=Fw7hk7L9IDsahNFrRoberta Glass True Crime Report “Will Karen Read's Magical Distraction Campaign Work” - https://www.youtube.com/live/Wrb5gLD8fkI?si=_GvM-hlHMT1aYoARYellow Cottage Tales Spaces on X (Kevin Lenihan) - https://x.com/ourx_vault/status/2016992286995824852?s=12Aidan Kearney on X - https://x.com/doctorturtleboy/status/2016966702714802633?s=46&t=QYSCN5--uh3-3EcMJ5GVBwThank you Patrons!Beth, Shelley Safford, Carol Mumumeci, Therese Tunks, JC, Lizzy D, Elizabeth Drake, Texas Mimi, Barb, Deborah Shults, Ratliff, Stephanie Lamberson, Maryellen Sudol, Mona, Karen Pacini, Jen Buell, Marie Horton, ER, Rosie Grace, B. Rabbit, Sally Merrick, Amanda D, Mary B, Mrs Jones, Amy Gill, Eileen, Wesley Loves Octoberfest, Erin (Kitties1993), Anna Quint, Cici Guteriez, Sandra Loves GatsbyHannna, Christy, Jen Buell, Elle Solari, Carol Cardella, Jennifer Harmon, DoxieMama65, Carol Holderman, Joan Mahon, Marcie Denton, Rosanne Aponte, Johnny Jay, Jude Barnes, JenTheRN, Victoria Devenish, Jeri Falk, Kimberly Lovelace, Penni Miller, Jil, Janet Gardner, Jayne Wallace (JaynesWhirled), Pat Brooks, Jennifer Klearman, Judy Brown, Linda Lazzaro, Suzanne Kniffin, Susan Hicks, Jeff Meadors, D Samlam, Pat Brooks, Cythnia, Bonnie Schoeneman-Dilley, Diane Larsen, Mary, Kimberly Philipson, Cat Stewart, Cindy Pochesci, Kevin Crecy, Renee Chavez, Melba Pourteau, Julie K Thomas, Mia Wallace, Stark Stuff, Kayce Taylor, Alice, Dean, GiGi5, Jennifer Crum, Dana Natale, Bewildered Beauty, Pepper, Joan Chakonas, Blythe, Pat Dell, Lorraine Reid, T.B., Melissa, Victoria Gray Bross, Toni Woodland, Danbrit, Kenny Haines and Toni Natalie.

01-28-26 - Entertainment Drill - WED - Potsie From Happy Days Is Related To Dr Heimlich - Questioning If Brady's Driver Assistance Feature Is Called Blues CruiseSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

From Andy Cohen and Anderson Cooper quietly moving on from Kathy Griffin years ago, to Blake Lively’s driver alleging a disturbing confession by Justin Baldoni, to the Beckhams laying down a shocking ultimatum to reunite with son Brooklyn — it’s another reminder that behind celebrity smiles lie fractured friendships, explosive claims, and family drama with strings firmly attached. Rob’s latest exclusives and insider reporting can be found at robshuter.substack.com His forthcoming novel, It Started With A Whisper, is now available for pre-orderSee omnystudio.com/listener for privacy information.

Am I the Jerk? is the show where you can confess your deepest darkest secrets and be part of the conversation.